licensingActimed retrieves ALS drug after Faraday collapseUK biotech Actimed Therapeutics has regained global rights to S-oxprenolol from the now-defunct Faraday Pharmaceuticals, giving it control of the experimental muscle-wasting drug across cancer cachexia, … more ➔
fundraisingMironid lands $46M Series B to take kidney drug into clinicScottish biotech Mironid has raised $46 million (€40 million) in a Series B financing to advance MR-L45, its small-molecule candidate for autosomal dominant polycystic kidney disease (ADPKD) through … more ➔
clinical trialEvexta pairs ex-Merck drug with Roche’s giredestrantFrench biotech Evexta Bio will combine its rupitasertib with Roche’s giredestrant in a Phase 1b trial targeting second-line, ESR1-mutated advanced breast cancer. more ➔
licensingAstraZeneca taps Pathos for breast cancer degraderAstraZeneca has put Pathos AI in charge of the early clinical development of AZD4241, its preclinical ERα degrader for ER-positive, HER2-negative breast cancer, under a co-exclusive licensing agree … more ➔
oncologyIpsen quietly returns cancer drug IPN01194 to AGV DiscoveryIpsen confirmed to European Biotechnology that it has stopped developing the Phase 1/2a ERK inhibitor IPN01194 and will return worldwide rights to French biotech AGV Discovery. more ➔
rare diseasesSobi’s dealmaker CEO exits for BioNTechGuido Oelkers will leave Swedish Orphan Biovitrum to become BioNTech’s CEO by Feb. 1, 2027, succeeding co-founder Uğur Şahin after overseeing a nine-year transformation that increased Sobi’s revenue … more ➔
M&AAstraZeneca explores $400B combination with BMSAstraZeneca has held talks with Bristol Myers Squibb over a potential combination that would create a pharmaceutical group worth nearly $400 billion (€348 billion), the Financial Times reported. more ➔
clinical dataZEUS failure clouds future of Novo’s cardiovascular plansNovo Nordisk’s ziltivekimab failed to reduce cardiovascular events in a Phase 3 trial, dealing a blow to a drug once forecast to generate about $3 billion in peak annual sales. more ➔
licensingPharmanovia licenses China-approved PARP drug for up to €423.5MUK specialty pharma Pharmanovia has licensed senaparib, IMPACT Therapeutics’ oral PARP1/2 inhibitor, across 66 countries in a deal worth up to €423.5 million. more ➔
artificial intelligenceRelation deepens GSK alliance with $110M dealLondon-based Relation Therapeutics has expanded its research collaboration with GSK in an agreement worth up to $110 million (€97 million), as the AI biotech launches a foundation model designed to … more ➔
